tradingkey.logo

MiMedx Group Inc

MDXG
查看详细走势图
6.900USD
-0.180-2.54%
收盘 12/26, 16:00美东报价延迟15分钟
1.02B总市值
24.93市盈率 TTM

MiMedx Group Inc

6.900
-0.180-2.54%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-2.54%

5天

-2.13%

1月

+0.29%

6月

+16.16%

今年开始到现在

-28.27%

1年

-26.52%

查看详细走势图

TradingKey MiMedx Group Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

MiMedx Group Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名48/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价12.20。中期看,股价处于平稳状态。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

MiMedx Group Inc评分

相关信息

行业排名
48 / 404
全市场排名
133 / 4563
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 5 位分析师
买入
评级
12.200
目标均价
+82.63%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

MiMedx Group Inc亮点

亮点风险
MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
业绩高增长
公司营业收入稳步增长,连续3年增长30.26%
估值高估
公司最新PE估值24.93,处于3年历史高位
机构减仓
最新机构持股104.90M股,环比减少3.52%
景顺投资公司持仓
明星投资者景顺投资公司持仓,最新持仓市值15.75K

MiMedx Group Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

MiMedx Group Inc简介

MiMedx Group, Inc. is a placental biologics company focused on providing a portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. Its product portfolio categories include Wound Care and Surgical. The Wound Care products include EPIFIX and EPIEFFECT, which are marketed for external use, such as in advanced wound care applications. Its EPICORD, EPICORD Expandable and EPIEFFECT product lines also offer an alternative treatment option to address larger, deeper wounds. Its Surgical and Other product offering includes AMNIOFIX and AMNIOEFFECT, which are used in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. It also offers HELIOGEN, an advanced bovine collagen matrix containing type I and type III collagen that is intended for the management of moderately to heavily exudating wounds and to control minor bleeding.
公司代码MDXG
公司MiMedx Group Inc
CEOCapper (Joseph H)
网址https://mimedx.com/

常见问题

MiMedx Group Inc(MDXG)的当前股价是多少?

MiMedx Group Inc(MDXG)的当前股价是 6.900。

MiMedx Group Inc的股票代码是什么?

MiMedx Group Inc的股票代码是MDXG。

MiMedx Group Inc股票的52周最高点是多少?

MiMedx Group Inc股票的52周最高点是9.710。

MiMedx Group Inc股票的52周最低点是多少?

MiMedx Group Inc股票的52周最低点是5.790。

MiMedx Group Inc的市值是多少?

MiMedx Group Inc的市值是1.02B。

MiMedx Group Inc的净利润是多少?

MiMedx Group Inc的净利润为42.42M。

现在MiMedx Group Inc(MDXG)的股票是买入、持有还是卖出?

根据分析师评级,MiMedx Group Inc(MDXG)的总体评级为买入,目标价格为12.200。

MiMedx Group Inc(MDXG)股票的每股收益(EPS TTM)是多少

MiMedx Group Inc(MDXG)股票的每股收益(EPS TTM)是0.277。
KeyAI